Overview

The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)

Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The goals of this project are to determine the effectiveness of acute (2 hours after a single dose) and chronic (after 6 weeks of once-a-day dosing) KNO3 treatment (10mmol) vs. placebo on quadriceps muscle power and on aerobic exercise performance (V̇O2peak) in patients with HFrEF (left ventricular ejection fraction <45%). The investigators hypothesize that both acute and chronic dosing of 10mmol of KNO3 will improve exercise performance in HFrEF. To test this hypothesis, the investors will perform a randomized, double-blind, placebo-controlled, parallel-arm design study.
Phase:
Phase 2
Details
Lead Sponsor:
Washington University School of Medicine